Fasenra (benralizumab) / AstraZeneca, Kyowa Kirin - LARVOL DELTA

Eosinophilic Granulomatosis with Poly-Angiitis (EGPA) : A Respiratory perspective (MTS 2025) - "Optimum treatment includes early Corticosteroid treatment , in combination with Rituximab or Cyclophosphamide, as remission induction therapy for EGPA, particularly for life or organ threatening disease. Novel clinical studies of Mepolizumab or Benralizumab as early anti-Interleukin-5/IL-5 Receptor antagonist eosinophil depleting therapy in EGPA are discussed, complementing conventional immunosuppression for remission induction in non-life threatening EGPA, and as early remission maintenance regimens, to facilitate corticosteroid weaning, to reduce steroid related co-morbidity and immunosuppression burden, and ensure long term maintenance remission. Rituximab, Methotrexate, mycophenolate or Azathioprine may be considered as alternative options when anti-IL-5/ IL-5R not available, or as adjunctive maintenance therapies depending on disease phenotype."

Allergic Bronchopulmonary Aspergillosis • ANCA Vasculitis • Asthma • Eosinophilia • Hematological Disorders • Immunology • Inflammation • Langerhans Cell Histiocytosis • Otorhinolaryngology • Pneumonia • Respiratory Diseases • Rheumatology • Vasculitis • IL5

Emerging drugs for the treatment of bullous pemphigoid: what's new on the horizon? (PubMed, Expert Opin Emerg Drugs) - "Only the inhibition of IL-4/IL-13 signaling by dupilumab met its primary endpoint...All strategies directly or indirectly targeting eosinophils, including the depletion of eosinophils by benralizumab, failed...Strategies targeting neutrophils, e.g. by inhibition of LTB4 should therefore be further pursued. Additionally, new kinase inhibitors, such as inhibitors of JAK, Syk, Src kinases, and BTK, should be tested because they would presumably inhibit multiple immune cell populations, including neutrophils, which is possibly required to achieve pronounced therapeutic effects in BP."

Journal • Review • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • IL13 • IL4 • SYK

CHECKLIST-GUIDED BIOLOGIC THERAPY IN SEVERE ASTHMA: A SINGLE-CENTRE EXPERIENCE (MTS 2025) - "Biologics prescribed included Omalizumab (n=4), Benralizumab (n=9), Dupilumab (n=8), and Tezepelumab (n=3). A structured checklist-based approach enhanced selection and monitoring. Access and funding limitations remain key barriers to sustained care."

Clinical • Asthma • Immunology • Inflammation • Respiratory Diseases

Severe Asthma, Biologic Hypersensitivity and Inefficacy: Overcoming Treatment Barriers with Tezepelumab. (PubMed, J Asthma) - "She experienced an allergic reaction with omalizumab and dupilumab and had inadequate response to benralizumab. Enrolled in an early access program for tezepelumab, she showed remarkable clinical improvement, with significant FEV1 increase and FeNO reduction, allowing discontinuation of systemic corticosteroids and supplemental oxygen."

Journal • Allergy • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • TSLP

Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review. (PubMed, J Pers Med) - "Emerging biomarkers, or older biomarkers with emerging utility, include sputum inflammatory cells (eosinophils, neutrophils, interleukins), thymus and activation-regulated chemokine (TARC), plasma eotaxin-3, eosinophil peroxidase (EPX), Clara/club cell secretory protein (CC16), and quantitative computerized tomography (QCT) imaging biomarkers (evaluating mucus plugging, air trapping, airway wall thickness, small airway remolding) and are increasingly used in clinical trials as secondary endpoints in evaluating efficacy, as well as in the clinical setting at specialized centers. The rapid advances in asthma research, due in part to biomarkers and biologic therapies, may soon standardize an end goal: symptom-free asthma remission without exacerbations."

Biomarker • Journal • Review • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • POSTN

The use of biologic therapies in pediatric severe asthma. (PubMed, Expert Rev Respir Med) - "This review provides an overview of the current evidence on biologic therapies approved for pediatric severe asthma, including omalizumab, mepolizumab, benralizumab, and dupilumab...We also examine emerging biologic agents targeting upstream pathways, such as tezepelumab and anti-IL-33 therapies, and explore the concept of asthma remission and its implications for long-term disease trajectories...However, challenges persist in optimizing patient selection, enhancing access, and comprehending long-term outcomes. Future research should focus on early intervention strategies, cost-effectiveness analyses, and the potential for disease-modifying effects in children."

Journal • Review • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases • IL33

Monoclonal Antibodies' Efficacy on Dysphagia Symptoms and Histological Remission in Patients With Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis (ACG 2025) - "We included 5 studies, with 1 study reporting 2 independent trials. Consequently, 6 RCTs comprising 631 patients were included in the final analysis. All RCTs compared monoclonal antibodies with a placebo, with 145 patients treated with dupilumab, 103 received benralizumab, 32 received mepolizumab, 34 received RPC4046, and 317 individuals assigned to the placebo group."

Retrospective data • Review • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • IL13 • IL4 • IL5

The Efficacy and Safety of Intranasal Corticosteroids in Chronic Rhinosinusitis: A Systematic Review. (PubMed, Cureus) - "Dupilumab demonstrated the greatest NPS reduction (Δ-2.06), improved nasal congestion, and reduced the need for surgery or systemic steroids. Mepolizumab, omalizumab, and benralizumab were also effective in reducing polyp size and symptoms, particularly in eosinophilic CRS. EDS-FLU (exhalation delivery system with fluticasone) improved congestion, SNOT-22 (22-item Sino-Nasal Outcome Test) scores, and reduced acute exacerbations...All interventions were well tolerated, with few adverse events reported. Overall, INCS are effective in managing CRS symptoms and reducing disease burden, particularly when combined with biologics or advanced delivery systems, and remain a cornerstone of CRS management with a strong safety and efficacy profile across diverse populations."

Journal • Review • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Pediatrics • Respiratory Diseases • Sinusitis

Guideline-driven and dependable management of asthma: an evidence-based systematic review. (PubMed, Ann Med Surg (Lond)) - "Biologics like dupilumab and benralizumab showed consistent reductions in severe asthma exacerbations. Findings affirm guideline-based therapy as foundational while highlighting the growing role of biologics and digital innovations. Our review received no external funding and was not registered in a systematic review registry."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Silent Swarms: Incidental Discovery of Eosinophilic Colitis in an Asymptomatic Adult (ACG 2025) - "Dietary elimination and corticosteroids (e.g., budesonide or prednisone) are commonly used. Emerging biologics like benralizumab and dupilumab show promise in targeting eosinophilic inflammation, though data remain limited. About 33% of patients experience acute flares, while 66% exhibit chronic persistence. Long-term surveillance is not standardized; however, close clinical monitoring is essential, especially in asymptomatic cases like ours, to detect disease progression and guide management."

Clinical • Cardiovascular • Diabetes • Endocrine Disorders • Eosinophilia • Gastroenterology • Gastrointestinal Disorder • Hepatitis C • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders

Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness. (PubMed, Front Pharmacol) - "From a pharmacoeconomic perspective, dupilumab has been found to be cost-effective in Japan compared to other biologics such as benralizumab and mepolizumab for asthma treatment. It is approved as an add-on maintenance therapy for patients aged ≥6 years with moderate-to-severe asthma, particularly those with T2 inflammation. By maximizing clinical and economic benefits through precision-guided patient selection, dupilumab's dual IL-4/IL-13 blockade makes it a versatile biologic-especially suited for T2-high and overlapping asthma phenotypes or patients with comorbidities such as nasal polyps, eosinophilic esophagitis, and atopic dermatitis."

Clinical data • HEOR • Journal • Review • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Eosinophilia • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • IL13 • IL4R

Breaking new ground biologic in COPD: Beyond the usual puff (MTS 2025) - "The most significant advancement is the FDA approval of dupilumab, an anti-IL-4/IL-13 monoclonal antibody, for COPD patients with type 2 inflammation...Other biologics under investigation include anti-IL-5 agents like mepolizumab and benralizumab, which target eosinophilic inflammation, and anti-alarmins such as itepekimab, astegolimab, tozorakimab and tezepelumab, which interfere with epithelial-derived cytokines like IL-33 and TSLP...Biomarkers such as blood eosinophil count, FeNO, and mucus scoring techniques (CT-based and bronchoscopic) are becoming essential tools in identifying candidates for biologic therapy. This biologic revolution signals a departure from standard inhaler-based regimens, offering a new frontier in COPD management where therapy is matched to inflammatory phenotype—marking a bold step forward in precision respiratory medicine."

Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Respiratory Diseases • IL13 • IL33 • IL4 • IL5 • TSLP

Steady Quiet Asthma Without Biologics: One-Year Outcomes of Single-Inhaler Triple Therapy for Severe Asthma with Small Airway Dysfunction. (PubMed, J Clin Med) - "When prescribed, biologic therapies included mepolizumab, benralizumab, and dupilumab. Baseline Fres, FEV1/FVC ratio, and %FEV25-75 are valuable predictors of achieving Steady Quiet Asthma (SQA) and sparing biologic therapy. These findings support the use of SITT in severe asthma and highlight the importance of early functional assessments to guide personalized management."

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

ECONOMIC BURDEN OF BIOLOGICS IN RESPIRATORY DISEASES: ANALYZING MEDICARE SPENDING ON MEPOLIZUMAB, BENRALIZUMAB, AND DUPILUMAB USING MEDICARE, PART D (CHEST 2025) - No abstract available

HEOR • Medicare • Reimbursement • US reimbursement • Respiratory Diseases

A Study of 10 Cases of Eosinophilic Otitis Media Treated with Biologics (AAO-HNSF 2025) - "The use of biologics for eosinophilic otitis media is expected to improve both the eosinophilic otitis media severity score and the pure tone threshold.In the chronic otitis media type with granulation, the granulation improved, but there was little improvement in severity score and hearing level."

Clinical • Asthma • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE. (PubMed, ERJ Open Res) - "Additionally, dupilumab significantly reduced OCS prescriptions by 25% versus omalizumab, 27% versus benralizumab and 21% versus mepolizumab. The findings suggest that dupilumab may reduce severe exacerbations and OCS use in patients with SA better than omalizumab, benralizumab and mepolizumab in European real-world settings."

HEOR • Journal • Real-world evidence • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Late Breaking Abstract - Clinical Remission in Patients with Severe Eosinophilic Asthma Treated with Benralizumab over 24 Months: Post Hoc Analysis of the ANANKE Study (ERS 2025) - No abstract available

Clinical • Late-breaking abstract • Retrospective data • Asthma • Immunology • Respiratory Diseases

Inhaled Corticosteroid Reduction Effects on Asthma Outcomes after Three Years of Benralizumab Treatment in Severe Asthma Patients (ERS 2025) - No abstract available

Clinical • Asthma • Immunology • Respiratory Diseases

Enhancing Clinical Remission and Reducing Health Care Utilization in Severe Eosinophilic Asthma: Real-World Benefits of Benralizumab in Belgium (ERS 2025) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2 (ERS 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Stringent American (ATS/ACAAI/AAAAI) endorsed 6-component definition of asthma remission is not achievable in a real-world benralizumab cohort (ERS 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Benralizumab efficacy in a real-life cohort of severe asthma and eosinophilic granulomatosis with polyangiitis patients (ERS 2025) - No abstract available

Clinical • Asthma • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Langerhans Cell Histiocytosis • Rare Diseases • Respiratory Diseases • Vasculitis

Changes in airway structure/function with benralizumab treatment of severe eosinophilic asthma (SEA) observed with Functional Respiratory Imaging (FRI) (ERS 2025) - No abstract available

Asthma • Immunology • Respiratory Diseases

Effects of benralizumab on T cell adhesion molecules in severe eosinophilic asthma: modulation by IL-25 and IL-33 (ERS 2025) - No abstract available

Asthma • Immunology • Respiratory Diseases • IL33

Benralizumab affects specific compartments in severe asthma patients with chronic rhinosinusitis and nasal polyposis (ERS 2025) - No abstract available

Clinical • Asthma • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis